During the fourth quarter of 2009, Biogen Idec repurchased 14.8 million shares of stock at a total cost of $694 million. Two share repurchase authorizations ...
After integrating the PAS into the health economic analysis, the breakdown indicated that STELARA would result in cost savings compared to continuous use of ...
Analysis showed that current annual costs ranged from $1197 for methotrexate (Rheumatrex, Trexall), at 7.5 milligrams a week, to $27577 for two 12-week ...
On January 20, the European Commission approved ORENCIA(R) in combination with methotrexate for the treatment of moderate to severe active polyarticular ...
The new drug is licensed for use in combination with methotrexate (MTX), for the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult ...
Specifically, RoActemra (tocilizumab) has been recommended for use in combination with methotrexate to treat patients with moderate-to-severe active RA who ...
The drug will mainly be given alongside methotrexate, a standard anti-inflammatory. Rheumatoid arthritis is a debilitating joint condition which cause ...
Adjuvant studies require thousands of women to show survival benefits, at high cost and often long follow-up. Studies such as NOAH illustrate the benefits ...
Email this story
